Full Press Release Details
Citius Pharmaceuticals Regains Compliance with
Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J., July 8, 2025 - Citius Pharmaceuticals,
Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification
from The Nasdaq Stock Market LLC ("Nasdaq") indicating that for 10 consecutive trading
days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock was at $1.00 per share or greater,
and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). The previously scheduled Nasdaq Hearing Panel has
been cancelled. Nasdaq informed the Company that Citius Pharma's securities will continue to be listed and traded on the Nasdaq Stock Market.
"We are pleased to have regained compliance
with Nasdaq's minimum bid price requirement," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. "This
reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders."
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is
a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024,
the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's
late-stage pipeline also includes Mino-Lok , an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream
infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a
Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively
engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information,
please visit www.citiuspharma.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You
can identify these statements by the fact that they use words such as "will," "anticipate," "estimate,"
"expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ
materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability
to maintain compliance with Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product
candidates that may be approved by the FDA; our ability to use the latest technology to support our commercialization efforts; our need
for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future
distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for
our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of
our target patient populations; risks relating to the results of research and development activities, including those from our existing
and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability
to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and
clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent
and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully
and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been
and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees
of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business
are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website
VP, Corporate Communications & Investor Relations
Citius Pharmaceuticals, Inc.
908-967-6677 ext. 113
908-967-6677 ext. 113